Health Care • Other Pharmaceuticals
$330.53 ▲ +6.18
(+1.91%)
MKT CAP: $63.07B • VOL: 1.03M
52W L $245 52W H $378
COR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $321.33B | $293.96B | $262.17B |
| YoY Revenue Growth % | +9.3% | +12.1% | — |
| Gross Profit | $11.48B | $9.91B | $115.36B |
| Gross Margin % | 3.6% | 3.4% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $2.63B | $2.18B | $2.34B |
| Operating Margin % | 0.8% | 0.7% | 0.9% |
| Net Income (GAAP) | $1.55B | $1.51B | $1.75B |
| EBITDA (Normalized) | $3.16B | $2.56B | $11.78B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $3.88B | $3.48B | $3.91B |
| Capital Expenditures (CapEx) | $668.0M | $487.2M | $11.80B |
| Free Cash Flow (FCF) | $3.21B | $3.00B | -$7.89B |
| FCF Margin % | 1.0% | 1.0% | -3.0% |
| Return on Invested Capital (ROIC %) | 26.8% | 58.5% | 1.0% |
| Cash & Short-Term Equivalents | $1.75B | $3.22B | $34.61B |
| Total Debt (Short + Long Term) | $7.58B | $5.94B | $73.62B |
| Total Stockholders' Equity | $1.91B | $226.6M | $151.01B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR COR.